PTC Therapeutics raised its 2026 revenue outlook on October 29 while reporting a third-quarter net loss of $51.7 million, compared with net income of $15.9 million a year earlier.
The company now expects annual total revenue of $1.29 billion to $1.32 billion. It increased product-revenue guidance to $960 million–$990 million from $850 million–$950 million.
Quarterly product and royalty revenue totaled $357.6 million, compared with $201.7 million a year earlier. Product revenue alone increased to $275.9 million from $131 million.
Sephience contributed $181.9 million, up 20% from the preceding quarter. Translarna sales declined to $48.5 million from $50.7 million, while Emflaza sales fell to $25.1 million from $35.2 million.
PTC recorded $111 million in acquired research-and-development expense related to its purchase of the ST-920 gene-therapy program. GAAP research-and-development expenses were $105.4 million, compared with $100.2 million a year earlier.
Cash, cash equivalents and marketable securities totaled approximately $2.13 billion at September 30.
The annual outlook is a financial forecast. The sales figures do not independently establish clinical effectiveness or future regulatory approval.
Sources: PTC Therapeutics — October 29 Results: https://ir.ptcbio.com/news-releases/news-release-details/ptc-therapeutics-provides-corporate-update-and-reports-third-4 PTC — October 29 Form 8-K Exhibit: https://www.stocktitan.net/sec-filings/PTCT/8-k-ptc-therapeutics-inc-reports-material-event-ed099d9507b6.html